Amandeep S. Sidhu
Subscribe to Amandeep S. Sidhu's PostsAmandeep (Aman) S. Sidhu focuses his practice on complex commercial disputes with an emphasis on regulated industries, including health care-related investigations and litigation. He represents hospitals and health care companies in investigations and defense of qui tam whistleblower litigation involving federal False Claims Act (FCA), Stark Laws and Anti-Kickback Statute in federal district courts throughout the United States. Aman regularly supports settlement negotiations with the US Department of Justice for clients in multiple jurisdictions, including negotiation of corporate integrity agreements with the US Department of Health and Human Services Office of Inspector General. Aman also represents health care and life sciences companies in the navigation of state and federal investigations, including responding to congressional inquiries. Aman serves on the Firm's Diversity/Inclusion Committee, Pro Bono and Community Service Committee and Associate Development Committee. Read Amandeep Sidhu's full bio.
Healthcare Enforcement Quarterly Roundup – Q2 2019
By Amandeep S. Sidhu, David Quinn Gacioch, Drew Elizabeth McCormick, Edward G. Zacharias, Irene A. Firippis, Jennifer Aronoff, Jennifer B. Routh, Katrina Rogachevsky, Lauren Evans, Laura McLane, Marshall E. Jackson, Jr., Paul M. Thompson, Sophia A. Luby, Theodore Alexander and Tony Maida on Aug 27, 2019
Posted In Additional Compliance Resources, Compliance Developments, Other Notable Enforcement Actions, Pharmaceuticals
In this second installment of the Healthcare Enforcement Quarterly Roundup for 2019, we cover several topics that have persisted over the past few years and identify new issues that will shape the scope of enforcement efforts for the remainder of this year and beyond. In this Quarterly Roundup, we discuss DOJ’s guidance on compliance programs and cooperation credit,...
Continue Reading
First of Its Kind: Drug Wholesaler Accepts DPA and Two Executives Face Criminal Charges in SDNY For Illegal Distribution of Opioids
By Amandeep S. Sidhu and T. Reed Stephens on May 6, 2019
Posted In Compliance Developments, Director and Officer Liability and Accountability, Government investigation, Knowledge/Scienter, Pharmaceuticals, Yates Memorandum
On April 23, 2019, the US Department of Justice (DOJ) announced it has entered into a deferred prosecution agreement with Rochester Drug Co-Operative, Inc. (RDC), one of the 10 largest wholesale distributors of pharmaceutical products in the US, and filed felony criminal charges against two of RDC’s former senior executives for unlawful distribution of controlled...
Continue Reading
Health Care Enforcement Quarterly Roundup – Q1 2019
By McDermott Will & Emery, Amandeep S. Sidhu, Drew Elizabeth McCormick, Irene A. Firippis, James A. Cannatti III, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti, Paul M. Thompson, Sean Hennessy, Sophia A. Luby, Theodore Alexander, Tony Maida and T. Reed Stephens on Apr 26, 2019
Posted In Additional Compliance Resources, Other Notable Enforcement Actions, Pharmaceuticals
In this first installment of the Health Care Enforcement Quarterly Roundup for 2019, we continue to monitor trends we identified in 2018 and introduce new enforcement efforts that are expected to persist in the coming year. In this Roundup, we focus on increased enforcement activity against electronic health record (EHR) companies, enforcement against individuals (with an acute focus...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q4 2018
By Sophia A. Luby, Theodore Alexander, Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amandeep S. Sidhu, Irene A. Firippis, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti, Natalie Colvin and Paul M. Thompson on Jan 30, 2019
Posted In Compliance Developments, Other Notable Enforcement Actions, Yates Memorandum
This latest installment of the Health Care Enforcement Quarterly Roundup reflects on trends that persisted in 2018 and those emerging trends that will carry us into 2019 and beyond. Leading off with the US Department of Justice’s (DOJ) December announcement of its fiscal year 2018 False Claims Act (FCA) recoveries, it remains clear that the...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q3 | September 2018
By Paul M. Thompson, Sophia A. Luby, Theodore Alexander, Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amy H. Kearbey, Amandeep S. Sidhu, Irene A. Firippis, Jennifer B. Routh, Laura McLane, Matthew M. Girgenti and Natalie Colvin on Oct 8, 2018
Posted In Compliance Developments, Other Notable Enforcement Actions
In the latest installment of Health Care Enforcement Quarterly Roundup, we examine key enforcement trends in the health care industry that we have observed over the past few months. In this issue, we report on: Practical applications of recent guidance from the US Department of Justice (DOJ) A recent blow to DOJ’s effort to use...
Continue Reading
Insys Announces Settlement-in-Principle with DOJ Over Alleged Subsys Kickback Scheme
By Amandeep S. Sidhu and Matthew M. Girgenti on Sep 13, 2018
Posted In Anti-Kickback Statute / Stark Law, Government investigation, Other Notable Enforcement Actions, Pharmaceuticals, State Law Claims, Yates Memorandum
Last month, Insys Therapeutics, Inc. announced that it reached a settlement-in-principle with the U.S. Department of Justice (DOJ) to settle claims that it knowingly offered and paid kickbacks to induce physicians and nurse practitioners to prescribe the drug Subsys and that it knowingly caused Medicare and other federal health care programs to pay for non-covered...
Continue Reading
Health Care Enforcement Quarterly Roundup | Q2 | July 2018
By Laura McLane, Matthew M. Girgenti, Monica Wallace, Natalie Colvin, Paul M. Thompson, Sandra M. DiVarco, Stephen W. Bernstein, Sophia A. Luby, Tony Maida, T. Reed Stephens, McDermott Will & Emery, Amandeep S. Sidhu, David S. Rosenbloom and Emily J. Cook on Jul 18, 2018
Posted In Compliance Developments, Other Notable Enforcement Actions
How will key trends and developments in health care policy and enforcement impact future litigants? In the latest Health Care Enforcement Quarterly Roundup, we address this question in the context of: Continued interpretations of the landmark Escobar case The latest guidance from US Department of Justice (DOJ) leadership regarding enforcement priorities The uptick in state...
Continue Reading
Register today! Health Care Enforcement Q2 Roundup Webinar
By Amandeep S. Sidhu, Laura McLane, Paul M. Thompson and Tony Maida on Jul 2, 2018
Posted In Compliance Developments, Government investigation, Other Notable Enforcement Actions, Public Disclosure Bar
Health Care Enforcement Q2 Roundup Webinar Date: Tuesday, July 17, 2018 Time: 11:00 am PDT | 12:00 pm MDT | 1:00 pm CDT | 2:00 pm EDT REGISTER NOW How will recent developments and emerging trends related to health care fraud and abuse impact future investigation targets and litigants? Our upcoming Health Care Enforcement Quarterly...
Continue Reading
New DOJ Task Force to Take on Opioid Crisis Using the FCA and Other Enforcement Tools
By Amandeep S. Sidhu, Matthew M. Girgenti and Paul M. Thompson on Mar 2, 2018
Posted In Additional Compliance Resources, Compliance Developments, Government investigation, Other Notable Enforcement Actions, Pharmaceuticals
Earlier this week, the US Department of Justice (DOJ) launched a new front in its effort to combat the opioid crisis and explicitly stated that it will deploy the False Claims Act (FCA) as part of its offensive. In a press release and parallel speech delivered by Attorney General Jeff Sessions on February 28, 2018,...
Continue Reading
DOJ Issues Memorandum Outlining Factors for Evaluating Dismissal of Qui Tam FCA Cases in Which the Government Has Declined to Intervene
By McDermott Will & Emery, Amandeep S. Sidhu and T. Reed Stephens on Jan 29, 2018
Posted In Anti-Kickback Statute / Stark Law, Government investigation, Government Knowledge, Materiality, Other Notable Enforcement Actions, Pharmaceuticals, Public Disclosure Bar
As first reported in the National Law Journal, the US Department of Justice (DOJ), Civil Division, recently issued an important memorandum to its lawyers handling qui tam cases filed under the False Claims Act (FCA) outlining circumstances under which the United States should seek to dismiss a case where it has declined intervention and, therefore,...
Continue Reading
